Influence of the surfactant concentration on the body distribution of nanoparticles.
暂无分享,去创建一个
R. Löbenberg | J. Kreuter | L Araujo | R Löbenberg | J Kreuter | L. Araújo | Joerg Kreuter | Raimar Löbenberg
[1] R. Müller,et al. Correlation of the surface hydrophobicity of 14C-poly(methyl methacrylate) nanoparticles to their body distribution , 1992 .
[2] Martyn C. Davies,et al. In vitro cell interaction and in vivo biodistribution of poly(lactide-co-glycolide) nanospheres surface modified by poloxamer and poloxamine copolymers , 1997 .
[3] D. Hochstrasser,et al. Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting , 1996 .
[4] D. Bazile,et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.
[5] Danilo D. Lasic. Sterisch stabilisierte Vesikel , 1994 .
[6] G. Borchard,et al. Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. , 1993, Journal of drug targeting.
[7] R. Müller,et al. In vitro characterization of poly(methyl-methaerylate) nanoparticles and correlation to their in vivo fate , 1992 .
[8] J. Kreuter,et al. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants , 1990 .
[9] V. Torchilin,et al. Biodegradable long-circulating polymeric nanospheres. , 1994, Science.
[10] J. Kreuter. Evaluation of nanoparticles as drug-delivery systems. II: Comparison of the body distribution of nanoparticles with the body distribution of microspheres (diameter greater than 1 micron), liposomes, and emulsions. , 1983, Pharmaceutica acta Helvetiae.
[11] S. Davis,et al. The organ uptake of intravenously administered colloidal particles can be altered using a non‐ionic surfactant (Poloxamer 338) , 1984, FEBS letters.
[12] V. Kolb-Bachofen,et al. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. , 1993, Biochimica et biophysica acta.
[13] S. Davis,et al. The effect of hydrophilic coatings on the uptake of colloidal particles by the liver and by peritoneal macrophages , 1986 .
[14] C. Schroën,et al. Influence of preadsorbed block copolymers on protein adsorption: surface properties, layer thickness, and surface coverage. , 1995 .
[15] S. Davis,et al. Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration. , 1983, Journal of pharmaceutical sciences.
[16] R. Müller,et al. Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908 , 1993 .
[17] M. Peracchia. Colloidal drug delivery systems: J. Kreuter (Ed.), Marcel Dekker, New York, 1994, $125 , 1995 .
[18] R. Müller,et al. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer--poloxamine 908. , 1987, Life sciences.
[19] D. Hochstrasser,et al. Colloidal carriers for intravenous drug targeting: Plasma protein adsorption patterns on surface‐modified latex particles evaluated by two‐dimensional polyacrylamide gel electrophoresis , 1993, Electrophoresis.
[20] J. Kreuter,et al. Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. , 1992, Journal of microencapsulation.
[21] J. Kreuter,et al. The use of 60Co-γ-irradiation for the production of vaccines , 1978 .